Move freely; live fully™
Quicker Relief from Pain compared to high molecular weight (HMW) Hyaluronic Acid (HA) 6
Quicker Relief from Pain compared to placebo:
Demonstrable pain relief as soon as one week 7
Improved Function and Quality of Life:
enables joint mobility and patient function. 2,3,4,5,6,7
Proven to reduce analgesic consumption in patients with osteoarthritis:
compared to high molecular weight (HMW) Hyaluronic Acid (HA)4
Long Lasting Pain Relief:
Proven to reduce pain in patients with mild to moderate osteoarthritis for at least 6 months 1,2,3 4,5,6,7
Sinovial Patient Advisory Panel
Are you interested in shaping the future of patient education? IBSA is inviting patients to join our Musculoskeletal Patient Advisory Panel. By participating in any of our future online focus groups, you’ll have the opportunity to share your valuable insights and help guide the development of educational materials for patients like you.
If you’d like to be involved, please provide your contact details, and a member of our team will be in touch with more information.
OSTEOARTHRITIS (OA)
Osteoarthritis (OA) is a common condition in the UK, affecting an estimated 10 million people (6 million women and 4 million men). Of these, an estimated 5.4 million have knee OA, and 3.2 million have hip OA.
Each year, around 350,000 people are newly diagnosed with OA, with symptoms typically starting around the age of 55. These numbers highlight the widespread impact of OA on individuals and communities nationwide.
Support your joints, reduce your pain, and regain your mobility.
OUR PARTNER CLINICS
Contact us, or our partner clinics for Sinovial.
Access the HCP Portal
This section of the site contains information
for healthcare professionals only.
